Abemaciclib Persistence in Patients with HR+, HER2-, Node-Positive Early Breast Cancer: a Real-World Analysis.

ABSTRACT:

Introduction

Patients with node-positive, high-risk, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) can be treated with 2 years of abemaciclib plus endocrine therapy (ET) to improve invasive disease-free survival (IDFS; hazard ratio 0.68; absolute 7.6% 5-year IDFS benefit) over ET alone as observed in the monarchE trial. Most adverse events (AEs) from abemaciclib occurred early in treatment and could be managed with dose reductions while maintaining efficacy. Describing adjuvant abemaciclib dosing patterns and early treatment persistence in patients in a real-world node-positive EBC cohort provides new evidence on abemaciclib administration in clinical practice and may inform AE management.

Methods

Using t

SUBMITTER: Hudson K 

PROVIDER: S-EPMC12647491 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature